Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 351 - 400 out of 12,304

Document Document Title
WO/2017/023687A1
In one aspect, the present invention features a method of inhibiting proliferation and/or reducing survival of a cell comprising a GNAQ polynucleotide or polypeptide having a R183Q or Q209L mutation, comprising contacting the cell with p...  
WO/2017/024310A1
The present disclosure provides pyrrolopyrimidine nucleoside analogs of the Formula I, Formula IA, Formula IB, or Formula II and phospholipid conjugates and pharmaceutical compositions thereof wherein Rc and A are defined herein. Also pr...  
WO/2017/023694A1
This invention relates the use of Cortisol blockers (e.g., glucocorticoid receptor [GR] antagonists) for the treating or preventing viral infections, treating or preventing treatment resistant prostate cancer, treating or preventing neop...  
WO/2017/019581A1
The present invention is directed to processes for making Compounds of Formula (IV): (IV) and salts thereof, wherein B, X, R1, R2, R3 and R4 are defined herein.  
WO/2017/018360A1
Provided is an artificial nucleoside, or artificial nucleotide, that is a compound represented by formula (I) or a salt thereof. In formula (I), Bx is a pyrimidine base, thioxopyrimidine base, or purine base, R1, R2, R3 and R4 are hydrog...  
WO/2016/178876A3
The present invention is directed to compounds, compositions and methods for treating or preventing Flaviviridae family of viruses (including HCV, Yellow fever, Dengue, Chikungunya and West Nile virus), RSV, HEV, and influenza infection ...  
WO/2017/019918A1
Methods and compositions are provided for oligonucleotides that bind targets of interest. The targets include cells and microvesicles, such as those derived from various diseases. The oligonucleotides can be used for diagnostic and thera...  
WO/2017/009746A1
The present invention relates to an improved process for the preparation Sofosbuvir Formula (I). The present further relates to Sofosbuvir having a purity of greater than 99.5%.  
WO/2016/196735A3
The present disclosure provides procedures and intermediates for the preparation of Sofosbuvir, comprising the step of reacting a compound of formula 2: wherein R1 and R2 can independently be hydrogen or halogen, provided that at least o...  
WO/2017/001307A1
The present invention relates to compounds of formula (I), wherein R1 to R4 are as described herein, and their pharmaceutically acceptable salts, enantiomers or diastereomers thereof, and compositions including the compounds for use in t...  
WO/2017/004261A1
The present disclosure provides compounds comprising modified oligonucleotides for use in CRISPR. In certain embodiments, such modified oligonucleotides provide improved properties of crRNA. In cetain embodiments, such modified oligonucl...  
WO/2017/004203A1
In certain embodiments, a method of detection includes providing cells labeled with a first element tag bound to a target RNA sequence and a second element tag bound to a target protein. The method may further include ionizing a cell, or...  
WO/2017/004499A1
This invention relates to compositions and methods for the treatment of infection such as RSV, influenza, adenovirus, or rhinovirus.  
WO/2016/210232A1
Topical compositions comprising niacinamide mononucleotide to improve the appearance of aging skin and to prevent and treat skin aging; and methods of use of topical compositions comprising niacinamide mononucleotide to improve the appea...  
WO/2016/178876A9
The present invention is directed to compounds, compositions and methods for treating or preventing Flaviviridae family of viruses (including HCV, Yellow fever, Dengue, Chikungunya and West Nile virus), RSV, HEV, and influenza infection ...  
WO/2016/200447A1
Compositions containing a combination of nicotinamide riboside and pterostilbene for treating skin disorders, and methods of treating skin disorders using these compositions and their equivalents are described. The skin disorders that ar...  
WO/2016/201374A1
Described herein are sulfamide adenosine derivatives of Formula (I) or (II), and pharmaceutically acceptable salts, and pharmaceutical compositions thereof. Also provided are methods, uses, and kits involving the inventive compounds or p...  
WO/2016/201025A1
Provided herein are photocrosslinking reagents, crosslinkable proteins displaying photocrosslinking groups, crosslinked protein-protein complexes, and methods of use thereof.  
WO/2016/198948A1
Enzyme-based systems and methods for synthesizing the NAD precursors NMN and NaMN are disclosed. Such methods and systems utilize a mutated form of phosphoribosylpyrophosphate synthetase (PRS) that is superactive and/or other enzyme or e...  
WO/2016/195353A1
The present invention provides to a cytidine deaminase (CDA)-resistant compound selected from the group consisting of 1'-cyano-cytarabine, 1'-cyano-gemcitabine, 1'-cyano-5-azacytidine and 1'-cyano-5-aza-2'-deoxycytidine, a prodrug or an ...  
WO/2016/175901A3
This document describes materials and methods for, for example, producing 6-hydroxyhexanoic acid using a β-ketothiolase or synthase and an alcohol O-acetyltransferase to form a 6-acetyloxy-3-oxohexanoyl-CoA intermediate. This document d...  
WO/2016/196735A2
The present disclosure provides new procedures and intermediates for the preparation of Sofosbuvir.  
WO/2016/188943A1
The present invention relates to novel nucleoside derivatives of formula (I) as defined in claim 1, pharmaceutical compositions comprising the compounds, processes of preparation thereof, and methods of use thereof for treating cancer.  
WO/2016/188868A1
The invention relates to new nucleoside-lipid compounds with pH-sensitive dialkylorthoesterchains, to the process for their preparation and to their uses, in particular their use for transportation or vectorization of at least one therap...  
WO/2016/189040A1
A process for preparing a nucleoside phosphoramidate, in particular to a process for preparing sofosbuvir, wherein a phosphoramidate derivative is used as starting material.  
WO/2016/189287A1
The present disclosure relates to new compounds and their use as fluorescent labels. The compounds may be used as fluorescent labels for nucleotides in nucleic acid sequencing applications. The labels are advantageous due to their long S...  
WO/2016/189055A1
The present application relates to novel nucleoside derivatives of formula (I) as claimed in claim 1, pharmaceutical compositions comprising the compounds, processes of preparation thereof, and methods of use thereof for treating cancer.  
WO/2016/184361A1
Disclosed are a compound represented by general formula (I), and pharmaceutically acceptable salt thereof, wherein A is O or C=CH2; B is a nucleoside base; Z is a connecting bond or CHR4; when W is a connecting bond or C(O), R is CH(R')C...  
WO/2016/182984A1
The present disclosure provides methods of sequencing polynucleotides and compounds, compositions useful for sequencing of polynucleotides. The chemical compounds include nucleotides and their analogs which possess a sugar moiety compris...  
WO/2016/177300A1
Disclosed are a compound of formula I, and preparation method and intermediate thereof; the use of the compound of formula I in preparing a drug for treating viral infections; the use of the compound of formula I in preparing sofosbuvir ...  
WO/2016/174081A1
The present invention relates to novel pro-drugs of L-2'-deoxythreose nucleoside phosphonates, such as phosphoramidate, phosphorodiamidate and phospho-diester prodrugs. The invention also relates to a process for preparing these novel pr...  
WO/2016/176193A1
Disclosed herein is a method to specifically remove alloreactive T cells. In one example, the method includes culturing donor cells comprising donor T cells with recipient antigen presenting cells (APCs) to form a mixture of cells under ...  
WO/2016/123397A3
The present disclosure provides nucleoside analogs of Formula (I) or (II). The nucleoside analogs may show multiple tautomerism and may increase the mutation of an RNA and/or DNA (be mutagenic) of a virus or cancer cell. The multiple tau...  
WO/2016/168911A1
The present invention is directed to purine nucleoside analogs of the general formula (I) or salts and pharmaceutical compositions comprising such compounds and salts, which are useful as anti-protozoan agents. The invention is also dire...  
WO/2016/168735A1
In various embodiments, a cell culture medium, or a nucleoside cocktail transmission (NCT) medium for the culture of stem cells with improved genetic stability, cellular function and regeneration ability is provided. Illustrative culture...  
WO/2016/168750A1
The present invention provides nucleic acid probes comprising two quenchers of excited state energy, and methods of their use.  
WO/2016/160646A1
The present invention is directed to processs for making Compounds of Formula (II): (II), and salts thereof, wherein B, X, R2, R3, R4 R7, R8 and R9 are defined herein.  
WO/2016/159836A1
The invention relates to the field of organic chemistry and medicine, and more particularly to synthetic substances of the pyrimidine series, namely 2-chloro-5-phenyl-5H-pyrimido[5',4':5,6]pyrano[2,3-d]pyrimid ine-4-ol derivatives, havin...  
WO/2016/160524A1
The invention provides a process for the preparation of nicotinamide mononucleotide having formula (I): The method involves the protection of nicotinamide riboside by ketalization, followed by phosphorylation and then deprotection to pro...  
WO/2016/159374A1
 The present invention provides a method for producing glycoside compounds represented by general formula (I) or salts thereof, said method comprising: a step (step 0) in which a thioether compound represented by general formula (103) ...  
WO/2016/156512A1
A process for preparing a solid crystalline form of sofosbuvir of formula (I) having an X-ray powder diffraction pattern comprising no reflection at 2-theta angles in the range of from 2.0 to 7.8 0 and preferably comprising reflections a...  
WO/2016/155593A1
The present invention relates to a novel compound of 4'-thionucleoside, a preparation method therefor, a pharmaceutical composition comprising the same and an application thereof. Specifically, the present invention relates to a phospham...  
WO/2016/161086A1
The invention provides compositions and methods for treating glycogen storage diseases or conditions with a buildup of glycogen. Cyclic AMP elevator compositions are shown to reduce glycogen storage in affected cells and therefore can be...  
WO/2016/154013A1
HAT-Pi chemotherapy arrests uncontrolled replication and metastatic migration of neoplastic cells by inhibiting enzymatic activity of poly (ADP-ribose) polymerase 1 (PARP 1) through administration of one or more halogenated analogs of th...  
WO/2016/151542A1
The present invention relates to an industrially applicable process for the preparation of phosphoramidates useful for the treatment of viral infections, such as sofosbuvir, and to intermediates useful for the preparation thereof. Formul...  
WO/2016/147185A1
Novel adenosine 5'-thiophosphate derivatives, represented by Formulae (I) or (I*), and salts thereof, represented by Formulae (Ia) and (I*a), as defined in the specification, and uses thereof as antioxidants and/or P2Y1-R agonists, and/o...  
WO/2016/146808A1
The invention relates to a new synthethic process for obtaining compounds of formula (I) from compounds of formula (II) by means of cytidine deaminase enzymes.  
WO/2016/149395A1
Derivatives of nicotinic acid riboside (NAR), nicotinamide riboside (NR), and reduced NAR and NR, including 1-(2', 3', 5'-triacetyl-beta-D-ribofuranosyl)-1,4-dihydronicotinic acid (4a), and compositions containing the same and/or reduced...  
WO/2016/145142A1
This disclosure relates to nucleotide and nucleoside therapeutic compositions and uses in treating infectious diseases, viral infections, and cancer, where the base of the nucleotide or nucleoside contains at least one thiol, thione or t...  
WO/2016/144918A1
A compound of the structure (A), or a pharmaceutically acceptable salt or composition thereof for the treatment of a host infected with or exposed to an HCV virus or other disorders more fully described herein.  

Matches 351 - 400 out of 12,304